News FocusPROTEOMICS

A Proteomics Upstart Tries to Outrun the Competition

See allHide authors and affiliations

Science  07 Dec 2001:
Vol. 294, Issue 5549, pp. 2079-2080
DOI: 10.1126/science.294.5549.2079

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

GENEVA, SWITZERLAND-- By assembling an arsenal of technology--including a research lab here in the outskirts of Geneva, one under construction in New Jersey, and a possible one in Japan--GeneProt, the biggest test-bed to date in the young field of proteomics, aims to identify proteins associated with disease. The company is banking that these proteins will produce a string of lucrative drugs aimed at top killers such as cancer and heart disease. GeneProt's moves have inspired both awe and skepticism among other proteomics researchers.

View Full Text

Stay Connected to Science